See more : Organto Foods Inc. (OGO.V) Income Statement Analysis – Financial Results
Complete financial analysis of Futura Medical plc (FAMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Futura Medical plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Warburg Pincus Capital Corporation I-A (WPCA-UN) Income Statement Analysis – Financial Results
- F.I.L.A. – Fabbrica Italiana Lapis ed Affini S.p.A. (FILA.MI) Income Statement Analysis – Financial Results
- Towa Pharmaceutical Co., Ltd. (TWAPF) Income Statement Analysis – Financial Results
- Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ) Income Statement Analysis – Financial Results
- Petro USA, Inc. (PBAJ) Income Statement Analysis – Financial Results
Futura Medical plc (FAMDF)
About Futura Medical plc
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.10M | 0.00 | 0.00 | 0.00 | 31.78K | 0.00 | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33M | 24.73K | 19.81K | 25.01K | 0.00 | 19.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.77M | -24.73K | -19.81K | -25.01K | 31.78K | -19.85K | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 57.22% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.05M | 4.13M | 3.77M | 1.93M | 10.05M | 6.04M | 4.10M | 3.51M | 4.78M | 2.37M | 1.98M | 1.44M | 1.00K | 762.00K | 810.00K | 1.40M | 1.52M | 1.08M | 1.55M | 960.00K | 627.00K | 811.00K | 683.00K | 207.00K |
| General & Administrative | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.82K | -4.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -47.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.74M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Cost & Expenses | 10.06M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Interest Income | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.00K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 133.00K | 177.00K | 48.00K | 60.00K | 22.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K | 29.00K | 16.00K |
| Depreciation & Amortization | 130.27K | 24.73K | 19.81K | 25.01K | 20.70K | 19.85K | 13.43K | 6.25K | 6.96K | 4.53K | 3.78K | 2.18K | 4.00K | 8.00K | 11.00K | 16.00K | 15.00K | 11.00K | 13.00K | 16.00K | 13.00K | 14.00K | 9.00K | 1.00K |
| EBITDA | -6.83M | -6.85M | -5.85M | -2.90M | -11.14M | -7.25M | -4.84M | -4.55M | -6.11M | -3.52M | -2.53M | -2.45M | -2.09M | -1.33M | -1.52M | -2.16M | -2.61M | -1.96M | -2.34M | -1.57M | -1.45M | -1.22M | -1.31M | -385.00K |
| EBITDA Ratio | -220.37% | 0.00% | 0.00% | 0.00% | -35,065.34% | 0.00% | -1,335.03% | -2,669.51% | -20,728.20% | -8,018.17% | -681.52% | -3,271.66% | -1,310.76% | -1,047.20% | -3,002.00% | -1,374.67% | -16,320.00% | 0.00% | -110,500.00% | -1,060.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.96M | -6.87M | -5.87M | -2.93M | -11.16M | -7.27M | -4.86M | -4.55M | -6.12M | -3.53M | -2.53M | -2.46M | -2.10M | -1.34M | -1.53M | -2.18M | -2.62M | -2.11M | -2.36M | -1.58M | -1.51M | -1.30M | -1.34M | -392.00K |
| Operating Income Ratio | -224.57% | 0.00% | 0.00% | 0.00% | -35,130.49% | 0.00% | -1,338.73% | -2,673.17% | -20,751.81% | -8,028.47% | -682.54% | -3,274.57% | -1,328.48% | -1,068.80% | -3,052.00% | -1,450.00% | -17,493.33% | 0.00% | -117,800.00% | -1,212.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.21K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 134.00K | 177.00K | 47.00K | 59.00K | -7.00K | -10.00K |
| Income Before Tax | -6.89M | -6.87M | -5.87M | -2.93M | -11.14M | -7.24M | -4.84M | -4.54M | -6.08M | -3.48M | -2.52M | -2.44M | -2.08M | -1.32M | -1.51M | -2.08M | -2.46M | -1.97M | -2.22M | -1.40M | -1.46M | -1.24M | -1.35M | -402.00K |
| Income Before Tax Ratio | -222.25% | 0.00% | 0.00% | 0.00% | -35,060.37% | 0.00% | -1,333.41% | -2,664.54% | -20,621.79% | -7,918.62% | -679.97% | -3,249.92% | -1,313.29% | -1,053.60% | -3,024.00% | -1,385.33% | -16,420.00% | 0.00% | -111,150.00% | -1,076.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -379.07K | -1.02M | -908.60K | -519.09K | -2.22M | -1.36M | -936.34K | -842.25K | -997.04K | -480.69K | -313.68K | -260.79K | -260.00K | -226.00K | -119.00K | -143.00K | -209.00K | -196.00K | -287.00K | -170.00K | -101.00K | -152.00K | -100.00K | -30.00K |
| Net Income | -6.51M | -5.85M | -4.96M | -2.41M | -8.92M | -5.88M | -3.90M | -3.70M | -5.08M | -3.00M | -2.21M | -2.18M | -1.82M | -1.09M | -1.39M | -1.94M | -2.25M | -1.78M | -1.94M | -1.23M | -1.36M | -1.09M | -1.25M | -372.00K |
| Net Income Ratio | -210.03% | 0.00% | 0.00% | 0.00% | -28,067.50% | 0.00% | -1,075.27% | -2,170.15% | -17,239.25% | -6,824.38% | -595.40% | -2,902.20% | -1,148.73% | -872.80% | -2,786.00% | -1,290.00% | -15,026.67% | 0.00% | -96,800.00% | -945.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| Weighted Avg Shares Out | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 43.15M | 40.96M | 30.88M | 27.36M |
| Weighted Avg Shares Out (Dil) | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 45.29M | 40.96M | 30.88M | 27.36M |
Futura Medical ticking all the boxes - but has the market caught up?
In investment circles, a company's inflexion points - key developments that can drive growth - often signal a rise in stock price. For Futura Medical PLC (AIM:FUM, OTC:FAMDF), several such events have unfolded recently, but its valuation seems slow to...
Futura Medical provides a glimpse of the future with two new products planned
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has announced positive developments for two prospective sexual health products, aiming to broaden its lineup and target both men's and women's health needs. The innovations — WSD4000 and Eroxon Intense — have completed initial proof-of-concept studies, and...
Futura Medical shares rise on $5m US milestone payment
Futura Medical PLC (AIM:FUM, OTC:FAMDF) shares rose 3% in early trading after the company secured a $5 million milestone payment following the US launch of its erectile dysfunction gel, Eroxon. The payment was triggered as distribution partner Haleon began fulfilling online...
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available...
Futura Medical consensus increases materially
Analysts following Futura Medical PLC (AIM:FUM, OTC:FAMDF) have updated and significantly upgraded revenue forecasts in the wake of its better-than-expected interims - results that saw the sexual healthcare group post a maiden profit ahead of schedule. It told investors that the City's...
Futura Medical CEO talks Eroxon growth and US launch - ICYMI
Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder talked with Proactive about the company's interim results, which included a maiden profit, along with the outlook for the business. The sexual health group increased guidance on both earnings and revenue for the...
Futura Medical: Doing what it says on the tube, says investment bank
'Doing what it says on the tube', was the headline from a Panmure Liberum report in the wake of Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s interim results. In summary, the numbers represented a landmark for management and shareholders as they revealed...
Futura posts maiden profit ahead of time; says revenue and earnings will 'significantly' exceed expectations
Futura Medical PLC (AIM:FUM, OTC:FAMDF) may have one eye on the upcoming US launch of its fast-acting erectile dysfunction gel Eroxon by healthcare giant Haleon. However, its financial performance in the first half of 2024 was possibly more worthy of...
Futura Medical says Eroxon will be available in US stores and online from October
Futura Medical PLC (AIM:FUM, OTC:FAMDF) provided keen investors with further details about the US launch plans for its fast-acting gel for erectile dysfunction from blue-chip partner Haleon PLC. The AIM-listed healthcare company said since yesterday, 1 September, Eroxon is now available for...
Futura Medical: Haleon ready launch Eroxon in the US before the year-end
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has received a boost from its blue-chip partner Haleon PLC (LSE:HLN, NYSE:HLN) on the timing of the US roll-out of Eroxon, Futura's fast-acting gel for erectile dysfunction. In its results statement earlier Thursday, the consumer...
Source: https://incomestatements.info
Category: Stock Reports